APA (7th ed.) Citation

Ogasawara, K., Dodds, M., Mack, T., Lymp, J., Dell’Aringa, J., & Smith, J. (2021). Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Clinical pharmacokinetics, 60(12), 1621-1633. https://doi.org/10.1007/s40262-021-01039-5

Chicago Style (17th ed.) Citation

Ogasawara, Ken, Michael Dodds, Timothy Mack, James Lymp, Justine Dell’Aringa, and Jeff Smith. "Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma." Clinical Pharmacokinetics 60, no. 12 (2021): 1621-1633. https://doi.org/10.1007/s40262-021-01039-5.

MLA (9th ed.) Citation

Ogasawara, Ken, et al. "Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma." Clinical Pharmacokinetics, vol. 60, no. 12, 2021, pp. 1621-1633, https://doi.org/10.1007/s40262-021-01039-5.